Evaluating the Immuno-Oncology Potential of Compounds Using Human In Vitro TME Models

Dr. Alison O’Mahony, Eurofins DiscoverX discusses the use of in vitro models of the human tumor microenvironment (TME) to qualify immuno-oncology candidates, prioritize combination strategies and predict clinical outcomes. She gives an overview on the recent failures of IDO inhibitors in the clinic and the immuno-oncology potential of anti-PD-1 antibodies including pembrolizumab.

Publish Date: June 18, 2018

Request Webinar Form

See other videos & webinars

Webinar: Evaluating the Immuno-Oncology Potential of Compounds Using Human In Vitro TME Models

To view the webinar, please complete the form, or sign in to your account.

I agree to receive future electronic communications from STEMCELL. I acknowledge that I can unsubscribe any time.

By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.

Request Pricing

Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):

Estimated delivery time for your area

Product sample or exclusive offer

In-lab demonstration

Evaluating the Immuno-Oncology Potential of Compounds Using Human In Vitro TME Models

Webinar: Evaluating the Immuno-Oncology Potential of Compounds Using Human In Vitro TME Models

Request Pricing

Related Multimedia

Qualification of Ancillary/Raw Materials for Clinical Use

Humanized Mouse Models for Hematopoietic Stem Cell Research: Principles and Pitfalls

Item added to your cart

Explore Our Products